

# European Journal of Nutrition

## Antiproliferative activity of vitexin-2-O-xyloside and avenanthramides on CaCo-2 and HepG2 cancer cells occurs through apoptosis induction and reduction of pro-survival mechanisms

--Manuscript Draft--

<b>Manuscript Number:</b>	EJON-D-16-00855	
<b>Full Title:</b>	Antiproliferative activity of vitexin-2-O-xyloside and avenanthramides on CaCo-2 and HepG2 cancer cells occurs through apoptosis induction and reduction of pro-survival mechanisms	
<b>Article Type:</b>	Original Contribution	
<b>Keywords:</b>	apoptosis; avenanthramides; CaCo-2 colon cancer cells; cellular antioxidant activity; HepG2 liver cancer cells; vitexin-2-O-xyloside	
<b>Corresponding Author:</b>	Paolino Ninfali, Ph.D University of Urbino "Carlo Bo" Urbino, PU ITALY	
<b>Corresponding Author Secondary Information:</b>		
<b>Corresponding Author's Institution:</b>	University of Urbino "Carlo Bo"	
<b>Corresponding Author's Secondary Institution:</b>		
<b>First Author:</b>	Emanuele Salvatore Scarpa	
<b>First Author Secondary Information:</b>		
<b>Order of Authors:</b>	Emanuele Salvatore Scarpa	
	Elena Antonini	
	Francesco Palma	
	Michele Mari	
	Paolino Ninfali, Ph.D	
<b>Order of Authors Secondary Information:</b>		
<b>Funding Information:</b>	University of Urbino "Carlo Bo"	Not applicable
<b>Abstract:</b>	<p><b>Purpose</b> - CaCo-2 colon cancer cells and HepG2 liver cancer cells represent two malignant cell lines, which show a high resistance to apoptosis induced by conventional anticancer drugs. Vitexin-2-O-xyloside (XVX) and avenanthramides (AVNs) are naturally occurring dietary agents from <i>Beta vulgaris</i> var. <i>cicla</i> L. and <i>Avena sativa</i> L., respectively. The aim of this work was to evaluate the antiproliferative effects and the reduction of the pro-survival mechanisms exerted by XVX and AVNs, used individually and in combination, in CaCo-2 and HepG2 cancer cells.</p> <p><b>Methods</b> - XVX and AVNs were isolated by liquid chromatography and characterized by HPLC-PDA-MS. The XVX and AVN antiproliferative effects were evaluated through sulforhodamine B method, while their pro-apoptotic effects through caspase activity assays. RTqPCR was used to investigate the modulation of the pro-survival factors Baculoviral Inhibitor of apoptosis Repeat-Containing 5 (BIRC5), Hypoxia Inducible Factor 1<math>\alpha</math> (HIF1A) and Vascular Endothelial Growth Factor (VEGFA). Cellular antioxidant activity (CAA) was investigated by means of DCFH-DA assay, whereas chemical antioxidant capacity was evaluated by the ORAC method.</p> <p><b>Results</b> - XVX and AVNs, both individually and in combination, inhibited the proliferation of CaCo-2 and HepG2 cancer cells, through activation of caspases 9, 8 and 3. XVX and AVNs downregulated the pro-survival genes BIRC5, HIF1A and VEGFA. The CAA assay showed that AVNs exhibited strong antioxidant activity inside both CaCo-2 and HepG2 cells.</p> <p><b>Conclusions</b> - The antiproliferative activity of the XVX+AVNs mixture represents an</p>	

	innovative treatment, which is effective against two types of cancer cells characterized by high resistance to conventional anticancer drugs.
<b>Suggested Reviewers:</b>	Fulvia Farabegoli fulvia.farabegoli@unibo.it
	David M Peterson dmpeter4@wisc.edu
	Jeffrey B Blumberg jeffrey.blumberg@tufts.edu
	Maria Skoglund maria.skoglund@lmv.slu.se

[Click here to view linked References](#)

1 **Antiproliferative activity of vitexin-2-O-xyloside and avenanthramides on CaCo-2 and HepG2 cancer cells**  
2 **occurs through apoptosis induction and reduction of pro-survival mechanisms**

3 Emanuele Salvatore Scarpa<sup>1</sup>, Elena Antonini<sup>1</sup>, Francesco Palma<sup>1</sup>, Michele Mari<sup>1</sup> and Paolino Ninfali<sup>1\*</sup>

4 <sup>1</sup> Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU) 61029, Italy

5 \*Correspondence to: paolino.ninfali@uniurb.it; Tel +39 0722 305288; Fax +39 0722 305324

6

7 **Abstract**

8 *Purpose* CaCo-2 colon cancer cells and HepG2 liver cancer cells represent two malignant cell lines, which show a high  
9 resistance to apoptosis induced by conventional anticancer drugs. Vitexin-2-O-xyloside (XVX) and avenanthramides  
10 (AVNs) are naturally occurring dietary agents from *Beta vulgaris* var. *cicla* L. and *Avena sativa* L., respectively. The  
11 aim of this work was to evaluate the antiproliferative effects and the reduction of the pro-survival mechanisms exerted  
12 by XVX and AVNs, used individually and in combination, in CaCo-2 and HepG2 cancer cells.

13 *Methods* XVX and AVNs were isolated by liquid chromatography and characterized by HPLC-PDA-MS. The XVX and  
14 AVN antiproliferative effects were evaluated through sulforhodamine B method, while their pro-apoptotic effects  
15 through caspase activity assays. RTqPCR was used to investigate the modulation of the pro-survival factors  
16 Baculoviral Inhibitor of apoptosis Repeat-Containing 5 (BIRC5), Hypoxia Inducible Factor 1A (HIF1A) and Vascular  
17 Endothelial Growth Factor (VEGFA). Cellular antioxidant activity (CAA) was investigated by means of DCFH-DA  
18 assay, whereas chemical antioxidant capacity was evaluated by the ORAC method.

19 *Results* XVX and AVNs, both individually and in combination, inhibited the proliferation of CaCo-2 and HepG2 cancer  
20 cells, through activation of caspases 9, 8 and 3. XVX and AVNs downregulated the pro-survival genes BIRC5, HIF1A  
21 and VEGFA. The CAA assay showed that AVNs exhibited strong antioxidant activity inside both CaCo-2 and HepG2  
22 cells.

23 *Conclusions* The antiproliferative activity of the XVX+AVNs mixture represents an innovative treatment, which is  
24 effective against two types of cancer cells characterized by high resistance to conventional anticancer drugs.

25

26 **Keywords** Apoptosis; avenanthramides; CaCo-2 colon cancer cells; cellular antioxidant activity; HepG2 liver cancer  
27 cells; vitexin-2-O-xyloside.

28 **Acknowledgments** We acknowledge the financial support of University of Urbino “Carlo Bo”. The authors wish also  
29 to thank: Terra Bio Soc. Coop. (Urbino, Italy) and Suba Seeds Company S.p.A. (Longiano, Italy) for providing oat  
30 grains and *Beta vulgaris* var. *cicla* L. seeds, respectively. Timothy Bloom is acknowledged for assistance in the English  
31 language.

## 32 **Introduction**

33 *Beta vulgaris* var. *cicla* L. (BVC; Chenopodiaceae) contains flavonoids that derive from apigenin, namely vitexin,  
34 vitexin-2-O-rhamnoside and vitexin-2-O-xyloside (XVX), which can exploit antiproliferative activity in several tumor  
35 cell lines [1, 2]. Studies have revealed that seeds of BVC are particularly rich in XVX, which has been purified in our  
36 laboratory and tested against RKO cells [3]. In these cells, it has been shown that XVX was able to induce apoptosis and  
37 to block the cell cycle in the G1 phase [3]. Moreover, in CaCo-2 and LoVo cancer cell lines, it has been shown that  
38 XVX was able to synergize with other anticancer phytochemicals, without any significant effect on the proliferation rate  
39 of normal cell lines [4, 5].

40 Oats (*Avena sativa* L.), which are normally consumed as whole grains, contain several antioxidant compounds, such as  
41 tocopherols, flavonoids, phenolic acids and avenanthramides [6]. Avenanthramides (AVNs), a group of substituted N-  
42 cinnamoylanthranilic acids, are soluble polyphenols exclusively found in oats, among cereals. More than 20 forms were  
43 identified by Collins in 1989, but the three most abundant are: AVN A, B and C, containing the *p*-coumaric, ferulic and  
44 caffeic acids, respectively, in the cinnamic moiety and the 5-hydroxyanthranilic acid in the anthranilic moiety [7].

45 AVN concentration varies considerably among varieties and it is influenced by genetic and environmental factors [8], as  
46 well as by the germination process [9, 10].

47 The bioavailability of AVNs has already been demonstrated in hamsters, rats and humans [11-13]. AVNs exhibit  
48 antioxidant, anti-inflammatory and anti-irritant activities *in vitro* and *in vivo* [14] and anti-proliferative properties, *in*  
49 *vitro* [15].

50 Apoptosis is a specific mechanism of cell death, which regulates tissue homeostasis, through the elimination of  
51 potentially deleterious cells [16]. Apoptosis is controlled by two pathways: the intrinsic pathway is regulated by the  
52 initiator caspase 9, leading to activation of executioner caspase 3; the extrinsic pathway is triggered by the interaction of  
53 the death ligand with its death receptor, leading to activation of initiator caspase 8 and then of caspase 3 [17].

54 The apoptotic program is controlled by a family of proteins called Inhibitor of Apoptosis Proteins (IAPs). Survivin,  
55 codified by the gene BIRC5, is a member of the IAPs family, that acts as a suppressor of apoptosis, through the  
56 inhibition of cleavage and activation of caspase 9 [18]. Survivin is over-expressed in several human neoplasms and it is  
57 currently used as a prognostic marker [19].

58 Other important factors, which control the survival of over-proliferating tumor cells, are the genes involved in  
59 angiogenesis and tumor progression [20]. These genes are mostly regulated by hypoxia inducible factors (HIFs) [21,  
60 22]. HIFs are heterodimers of two subunits: the constitutively expressed HIF1 $\beta$  and the oxygen responsive HIF1 $\alpha$ ; the  
61 latter is codified by the gene HIF1A [23]. HIF1A plays an oncogenic role in colorectal cancer, since its overexpression  
62 has been associated with higher mortality rate and shorter survival [24].

63 The protein HIF1 $\alpha$  controls the expression of several genes, such as VEGFA, which encodes for Vascular Endothelial  
64 Growth Factor (VEGF), the principal regulator of angiogenesis during tumor growth [25, 26]. VEGF is also able to  
65 inhibit apoptosis through up-regulation of IAPs [27].

66 CaCo-2 colon cancer cells are characterized by a mutated TP53 gene and overexpression of anti-apoptotic factors,  
67 which confer resistance to anticancer drugs [28]. HepG2 liver cancer cells are characterized by a wild type TP53 gene  
68 and mutations in the tumor suppressor gene Cyclin-Dependent Kinase inhibitor 2A [29], which confer high resistance to  
69 apoptosis induction [30]. From a pathophysiological point of view, colorectal carcinoma and hepatocarcinoma are  
70 linked, because the colorectal cancer is able to invade the primary tissue and generate liver metastases [31]. Therefore a  
71 drug, which shows remarkable activity against both cancer types, is relevant for chemoprevention.

72 This study was undertaken to set up the purification method of AVNs from oat sprouts, in order to test the  
73 antiproliferative effect of the AVNs+XVX combination on both CaCo-2 and HepG2 cancer cell lines. The mechanisms  
74 by which these phytochemicals induce apoptosis and downregulate the cancer cell pro-survival mechanisms were  
75 investigated as well.

## 76 **Materials and methods**

### 77 **Reagents and chemicals**

78 Ethanol and ethyl-acetate (analytical grade) were purchased from VWR International (Radnor, USA). DMEM culture  
79 medium, fetal bovine serum (FBS), antibiotics, trypsin, MEM non-essential amino acid solution, Sulforhodamine B  
80 sodium salt, water (LC-MS grade), acetonitrile (LC-MS grade), formic acid (LC-MS grade), glacial acetic acid, 2,2'-  
81 Azobis (2-amidinopropane) dihydrochloride (AAPH), 6-hydroxy-2,5,7,8-tetramethylchroman 2-carboxylic acid (Trolox),  
82 Fluorescein, H<sub>2</sub>O<sub>2</sub>, HBSS<sup>-</sup> (without calcium and magnesium) and DCFH-DA were purchased from Sigma-Aldrich (St.  
83 Louis, USA).

### 84 **AVN purification**

#### 85 *Oat sprouting*

86 Oat grains, provided by the local producer Terra Bio Soc. Coop. (Urbino, Italy), were steeped and germinated for 14  
87 and 72 hours, respectively, using an automatic sprouter (Fresh Life 2000, Corrupad Korea Co. Ltd., Korea), following  
88 the methods previously reported [9, 10]. Steeped and germinated oat grains were freeze-dried and stored at -20° C until  
89 analysis. Samples were milled in a ZM 200 ultracentrifugal mill with a 0.5 ring sieve (Retsch, Haan, Germany).

#### 90 *Extraction and isolation of AVNs*

91 AVNs were extracted from milled oat with acidified ethanol (1:10 w/v), following the procedure reported by us [8],  
92 with the exception that ethanol was acidified with 0.1% glacial acetic acid, instead of 10 mM H<sub>3</sub>PO<sub>4</sub> buffer.

93 The raw extract was concentrated by rotary evaporation to 1/10 of the initial volume. To remove lipophilic components  
94 from the extract, we followed the procedure reported by Liu et al [32], with some modifications. Briefly, Octyl  
95 Sepharose™ CL 4-B (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was added to the extract (0.5 ml per g  
96 extracted). The mixture was completely dried, re-suspended in acidified 50% ethanol and transferred to a glass  
97 chromatography column containing Octyl Sepharose™ CL 4-B, previously pre-equilibrated in acidified 50% ethanol.  
98 The column was then eluted with 3 x bed volume ( $V_b$ ) of acidified 50% ethanol. The eluate was concentrated under  
99 vacuum, at 40°C, by rotary evaporation.

100 The defatted dried extract was dissolved in acidified 30% ethanol and purified on a Sephadex LH-20 column (50 x 150  
101 mm; Sigma-Aldrich Inc., St. Louis, USA), equilibrated in acidified 30% ethanol, and controlled by the LC-  
102 Chromatograph AKTA Purifier 10 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The mobile phase was  
103 changed as follows: 2 x  $V_b$  of acidified 30% ethanol in isocratic mode to remove amino acids, free sugars, proteins, etc.  
104 [32]; 2 x  $V_b$  of acidified 50% ethanol in isocratic mode to remove the flavonoids and phenolic acids [32]; 2 x  $V_b$  of  
105 acidified ethanol from 50 to 95% in gradient mode, to recover the absorbed AVNs. The flow rate was 5 ml/min and  
106 absorbance values were obtained at 330 nm.

#### 107 ***HPLC-PDA-MS analysis of AVNs***

108 The dried fractions obtained from the Sephadex LH-20 column chromatography were dissolved in ethanol and directly  
109 analyzed in a Water instrument equipped with Alliance HT 2795 High Performance liquid Chromatography (HPLC),  
110 2996 Photo Diode Array (PDA) and Micromass LC/MS ZQ 2000 detector, following the procedure reported by us [8].  
111 To identify the individual AVNs in the HPLC chromatograms, retention time, UV spectra, MS ESI (+) and ESI (-)  
112 spectra were compared with those of commercially available external standards (AVN A, B, C, Sigma-Aldrich, St.  
113 Louis, USA), and the peak areas were used for quantification.

#### 114 **XVX purification**

115 XVX was isolated from seeds of BVc, obtained from Suba Seeds Company S.p.A. (Longiano, Italy). The extract from  
116 seeds was prepared by solid-liquid extraction with 70% ethanol in a Timatic extractor (Tecnolab S.r.l., Spello, Italy)  
117 and liquid-liquid extraction with ethyl-acetate. Two chromatography columns were applied: a Diaion HP-20 (Sigma-  
118 Aldrich, St. Louis, USA) and a Davisil C18 (ALLTECH, Milan, Italy), performed by means of the LC-Chromatograph  
119 AKTA Purifier 10, following the elution of XVX at 336 nm [3].

120 The HPLC analysis of XVX was performed using the same HPLC equipment used for AVNs, but a spherisorb ODS2  
121 column (4.6 x 250 mm; Waters Corporation, Milford, USA), with 5  $\mu$ m particle size was used. Standard and sample  
122 injected volumes were 20  $\mu$ l. The gradient consisted of 0.01% acetic acid in water (solvent A) and methanol containing

123 0.01% acetic acid (solvent B), developed as follows: from 0 to 60% solvent B in the interval 0-45 min at 1 ml/min, then  
124 to 100% B in the interval 45-50 min. XVX was identified using a purified standard available in our lab [3].

#### 125 **ORAC Assay**

126 Antioxidant activity was assessed using the ORAC (Oxygen Radical Absorbance Capacity) assay and a Fluostar Optima  
127 plate reader fluorimeter (BMG Labtech, Offenburgh, Germany) equipped with a temperature-controlled incubation  
128 chamber and automatic injection pump according to Ninfali et al [33]. Fluorescence was read at 485 nm ex. and 520 nm  
129 em. until complete extinction. ORAC values were expressed as  $\mu\text{mol Trolox Equivalents (TE) g}^{-1} \text{ d.m.}$ , which was used  
130 as external standard.

#### 131 **Cell cultures**

132 HepG2 liver cancer cell line and CaCo-2 colon cancer cell line were purchased from the American Type Culture  
133 Collection (ATCC, Rockville, USA) and maintained in DMEM supplemented with 10% FBS, 2 mM glutamine, 100  
134 U/ml penicillin, 100  $\mu\text{g/ml}$  streptomycin and 100  $\mu\text{M}$  MEM non-essential amino acid solution. NCTC 2544 normal  
135 human keratinocytes were obtained from Interlab Cell Line Collection (ICLC, Genova, Italy) and maintained in DMEM  
136 supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100  $\mu\text{g/ml}$  streptomycin. Cell lines were grown at  
137 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.

#### 138 **Sulforhodamine B (SRB) assay**

139 Cells ( $10^4/\text{well}$  for CaCo-2 and NCTC 2544;  $2 \times 10^4/\text{well}$  for HepG2) were plated in 96-well plates and treated with  
140 XVX and AVNs, both individually and in combination, for 24, 48 and 72 hours. At the end of treatment, cells were  
141 incubated with SRB as previously reported [5]. The results were expressed as the percentage of cell viability, compared  
142 to control untreated cells (100% viability).

#### 143 **DCFH-DA assay for Cellular Antioxidant Capacity (CAA) evaluation**

144 Cells were seeded ( $2 \times 10^5$  for CaCo-2 and  $3 \times 10^5$  for HepG2) in 6-well plates and treated for 24h with P4 or P3. After  
145 removing of cell medium, the production of ROS in CaCo-2 and HepG2 cells was monitored following the procedure  
146 reported by Farabegoli et al [5], with the substitution of PBS with HBSS <sup>-</sup> only. After incubation, the cells were  
147 observed at microscope with a green FITC filter (OLYMPUS IX51). Cells showing a bright and intense green  
148 fluorescence were counted as positive, whereas cells with no or low fluorescence were counted as negative. Three fields  
149 per sample were analyzed and each time at least 100 cells were counted. Three independent experiments were  
150 performed for both CaCo-2 and HepG2 cells and results were expressed as % DCF fluorescent positive cells versus  
151 control. The images were obtained using the software OLYMPUS Ps-blm1.

#### 152 **Determination of caspase 3, caspase 9 and caspase 8 activities**

153 HepG2 and CaCo-2 cells were untreated, or treated with 50  $\mu$ M XVX, 120  $\mu$ M P3, 120  $\mu$ M P4 or with 50  $\mu$ M  
154 XVX+120  $\mu$ M P4 for 48h, then the Petri dishes were put in ice and the cytosols were extracted following the procedure  
155 previously reported [34].

156 Caspase 3, caspase 9 and caspase 8 activities were assessed through the Caspase Colorimetric Assay Kit (BioVision,  
157 Milpitas, USA) according to the manufacturer's instructions. 100  $\mu$ g of cytosol from untreated or phytochemicals  
158 treated HepG2 and CaCo-2 cells were incubated with caspase reaction buffer (25 mM Hepes pH 7.4, 50 mM NaCl,  
159 0.05% CHAPS, 0.5 mM EDTA, 5% glycerol, 5 mM DTT), then the substrate (200  $\mu$ M final concentration) DMQD-  
160 pNA specific for caspase 3, or LEHD-pNA specific for caspase 9, or IETD-pNA specific for caspase 8 was added and  
161 the samples were transferred in a 96-wells microplate. All samples were incubated at 37°C for 2h. The absorbance,  
162 representing the activities of caspases, was measured at  $\lambda=405$  nm in a microplate reader (BioRad Laboratories,  
163 Hercules, USA).

#### 164 **RNA extraction, cDNA production and RTqPCR experiments**

165 Total RNA was extracted from CaCo-2 and HepG2 cells using the TriReagent (Invitrogen, Carlsbad, USA), following  
166 the manufacturer's protocol. cDNA production and RTqPCR assays were performed as previously reported [34]. The  
167 following list of primers was used:  $\beta$  -Actin F: 5'-GCGAGAAGATGACCCAGATC-3' , R: 5'-  
168 GGATAGCACAGCCTGGATAG-3' (77bp), BIRC5 F: 5'-ATTCGTCCGGTTGCGCTTTCC-3', R: 5'-  
169 CACGGCGCACTTTCTCCGCAG-3'(162bp), HIF1A F: 5'-TCTGGGTTGAAACTCAAGCAACTG-3', R: 5'-  
170 CAACCGGTTTAAGGACACATTCTG-3' (150 bp), VEGFA F: 5'-TCACAGGTACAGGGATGAGGACAC-3', R:  
171 5'-CAAAGCACAGCAATGTCCTGAAG-3' (72 bp).

#### 172 **Statistical analysis**

173 Data were expressed as mean  $\pm$  SD. Statistical significance was assessed by one-way ANOVA, using PRISM 5.1  
174 (GraphPad Software, La Jolla, USA). The results were considered statistically significant when  $p < 0.05$ .

175

## 176 **Results**

### 177 **Purification of AVNs**

178 AVNs were purified from oat sprouts, using the Sephadex LH-20 column chromatography. We obtained four main  
179 peaks, labeled as P1-P4 (Fig. 1a). The HPLC-PDA-MS analysis revealed that P1 and P2 peaks, contained hydrophilic  
180 contaminants and were discarded; P3 and P4, both containing AVNs, were collected and concentrated to dryness. From  
181 the HPLC-PDA-MS analysis, P3 revealed the presence of AVN B only, at 95% purity level (Fig. 1b); P4 revealed the  
182 presence of a mixture of AVN A, B, C, representing 80% of the whole weight (Fig. 1c). The structural formulae are  
183 shown in Fig. 1b and 1c. The relative % ratios of the AVN A, B, C of P4 are reported in Table 1. The concentrations

184 were accurately evaluated by HPLC, referring to calibration curves made with commercial AVN A, B, C standards. The  
185 remaining 20% of the P4 fraction was characterized by minor AVN forms (Fig. 1c; peaks 1-4), which were quantified  
186 using the commercial AVN A as external standard [32]. Our protocol for the chromatographic purification of AVN  
187 forms gave a reproducible profile in several repeated experiments (n=3). Our profile slightly differs from those of other  
188 authors [32]. It is worth to remember here that in the presentation of the following results, we used the label P3 for  
189 AVN B and P4 for the AVN mixture (AVN A, B, C).

#### 190 **Antioxidant capacity evaluation**

191 The antioxidant capacity, evaluated through the ORAC method, showed ORAC values of  $6,547 \pm 290$  and  $19,079 \pm 474$   
192  $\mu\text{mol TE/g}$  for P3 and P4, respectively (Table 1). The higher ORAC value of the P4 fraction should be related to the  
193 presence of AVN C, which is considered the most potent antioxidant form [35].

#### 194 **Purification of XVX**

195 XVX was purified in our laboratory from BVC seeds at 95% purity level. The XVX powder, stored at  $-20\text{C}$ , was used  
196 alone or in combination with AVNs for cell treatments. The purification protocol was tested along several years of  
197 reproducible experiments [3].

#### 198 **Antiproliferative effects of individual phytochemicals**

199 Earlier studies on normal human cells allowed us to choose the concentration range of XVX, P3 and P4 to be used in  
200 the dose response experiments of antiproliferative activity. As no cytotoxic effects were detected by us when XVX was  
201 used in the range  $0\text{-}100 \mu\text{M}$  and when AVNs were used in the range  $0\text{-}120 \mu\text{M}$  on normal NCTC 2544 cells (Online  
202 resource 1), we planned to evaluate antiproliferative effects on CaCo-2 and HepG2 cancer cells in this concentration  
203 range for XVX and for P3 and P4.

204 Fig. 2 shows the antiproliferative effects on CaCo-2 colon cancer cells (a, c, e) and HepG2 liver cancer cells (b, d, f) of  
205 the individual phytochemicals at 48h. At this treatment time, the maximum antiproliferative effect occurred.

206 On CaCo-2 cells, the  $\text{IC}_{50}$  values, at 48h were:  $50.9 \pm 5.5 \mu\text{M}$ ,  $126.5 \pm 12.5 \mu\text{M}$ ,  $114.6 \pm 5.5 \mu\text{M}$ , for XVX, P3 and P4  
207 respectively. Otherwise, on HepG2 cells, the  $\text{IC}_{50}$  values, at 48h were:  $71.6 \pm 7.4\mu\text{M}$ ,  $182.7 \pm 18.1 \mu\text{M}$ ,  $39.9 \pm 4.1 \mu\text{M}$   
208 for XVX, P3 and P4 respectively. Therefore, the XVX treatment was the most cytotoxic on CaCo-2 cells, while the P4  
209 treatment was the most cytotoxic on HepG2 cells.

#### 210 **Modulation of the caspase activities by individual phytochemicals**

211 XVX, P3 and P4 were used to investigate, at 48h, the ability of these phytochemicals to activate both the initiator  
212 caspases 8 and 9 and the effector caspase 3 in CaCo-2 and HepG2 cancer cells (Fig. 3).

213 The caspase 3 activity significantly increased on both CaCo-2 (Fig. 3a) and HepG2 (Fig. 3b) cancer cells with P4 and  
214 XVX treatments; otherwise, P3 was effective in CaCo-2 cells only.

215 The caspase 9 activity, linked to the “intrinsic” pathway of apoptosis, increased in the presence of XVX, but not in the  
216 presence of P4 or P3, on both CaCo-2 (Fig. 3c) and HepG2 (Fig. 3d) cancer cell lines.

217 In CaCo-2 cells, the caspase 8 activity, linked to the “extrinsic” apoptotic pathway, significantly increased in the  
218 presence of P4 and P3, but not in the presence of XVX (Fig. 3e); otherwise in HepG2 cells, only P4 was able to induce  
219 a significant increase in caspase 8 activity levels (Fig. 3f).

220 In other words, XVX activates the intrinsic apoptotic pathway, while AVNs activate the extrinsic apoptotic pathway, in  
221 both colon and liver cancer cells (Fig. 3).

#### 222 **Cellular antioxidant activity (CAA) of P4 and P3**

223 We incubated the CaCo-2 and HepG2 cells with P3 and P4, individually, in order to test their CAA, which is also an  
224 indication of the permeability of the phytochemicals through the cell membranes. The CaCo-2 cells (Fig. 4a) were  
225 treated for 24h with 60  $\mu$ M P4 and 60  $\mu$ M P3, whereas the HepG2 cells (Fig. 4b) with 30  $\mu$ M P4 and 120  $\mu$ M P3, before  
226 generating ROS by 1 mM H<sub>2</sub>O<sub>2</sub> for 1h. The choice of P4 and P3 concentrations was based on the minimum  
227 phytochemical concentration that showed a statistically significant antiproliferative effect on CaCo-2 and HepG2 cancer  
228 cells (Fig. 2).

229 P4 exerted a stronger CAA than P3 in both CaCo-2 (Fig. 4c) and HepG2 (Fig. 4d) cells, remarkably reducing the  
230 number of green fluorescent cells, after treatment with H<sub>2</sub>O<sub>2</sub>. These results suggest a link between the AVNs CAA and  
231 their antiproliferative effects on CaCo-2 and HepG2 cancer cells.

232 The intracellular antioxidant capacity of XVX was not investigated here, as it has already been demonstrated elsewhere  
233 [4, 36].

#### 234 **Molecular effects of the XVX+P4 mixture**

235 P4 only was chosen to be tested for the antiproliferative activity in combination with XVX. This choice was due to its  
236 lower IC<sub>50</sub> value, to the greater induction in caspase 8 and caspase 3 activity levels and to the higher CAA exerted in  
237 both cancer cell lines, when compared to P3.

238 CaCo-2 and HepG2 cells were incubated for 48h with XVX maintained at 50  $\mu$ M and P4 at the increasing  
239 concentrations of 30, 60 or 120  $\mu$ M. The combination 50  $\mu$ M XVX+120  $\mu$ M P4 showed the greatest antiproliferative  
240 effects on both cancer cell lines (Fig. 5a, 5b) and induced also the highest increase in the activity levels of caspase 3, 9  
241 and 8 in both CaCo-2 and HepG2 cancer cell lines (Table 2).

#### 242 **XVX+P4 mediated downregulation of BIRC5, HIF1A and VEGFA expression levels**

243 Through RTqPCR assays, we assessed whether XVX and P4, used alone and in combination, were able to reduce the  
244 expression levels of the pro-survival genes BIRC5, HIF1A and VEGFA in CaCo-2 and HepG2 cancer cells.

245 Our results (Fig. 6) showed a downregulation of the expression levels of the anti-apoptotic gene BIRC5 (survivin) by  
246 XVX and XVX+P4 on CaCo-2 (Fig. 6a) and HepG2 (Fig. 6b) cells. The treatment with P4 alone was ineffective on  
247 both cancer cell lines (Fig. 6a, 6b).

248 Individually, XVX and P4 were able to significantly downregulate the expression levels of HIF1A on both CaCo-2 (Fig.  
249 6c) and HepG2 (Fig. 6d) cancer cells. In addition, XVX+P4 showed a remarkable reduction ( $p < 0.001$ ) in HIF1A  
250 expression levels in both cancer cell lines (Fig. 6c, 6d).

251 XVX and P4, used alone, were also able to decrease the expression levels of VEGFA on both CaCo-2 (Fig. 6e) and  
252 HepG2 (Fig. 6f) cancer cells. The combination XVX+P4 showed a remarkable downregulation of the expression levels  
253 of VEGFA, with a greater extent on HepG2 than on CaCo-2 cells (Fig. 6e and 6f). In synthesis, XVX and P4 (AVNs),  
254 much better in combination than alone, markedly downregulated the expression levels of the genes HIF1A and VEGFA  
255 on both cancer cell lines, confirming data obtained with other flavonoids [37].

256

## 257 **Discussion**

258 The phytochemicals XVX and AVNs are purified in our lab from *Beta vulgaris* var *cicla* L. and *Avena sativa* L.,  
259 respectively. Green beet and oat are foods widely consumed in the Western and Eastern countries. With the ingestion of  
260 these foods, the above nutrients are absorbed in the gut and reach the liver through entero-hepatic recirculation [38]. By  
261 this way, these phytochemicals are bioavailable and able to exploit their biological effects in both colon and liver cells  
262 [38].

263 When a tumor develops in the colon, the cancer cells may spread into the liver and metastatize there [31]. Therefore, a  
264 couple of phytochemicals able to exploit biological effects on both colon and liver tissues, represent an important  
265 chemopreventive tool for subjects exposed to colon cancer risks, such as hereditary adenomatous polyposis [31].

266 In our study, we have evaluated the antiproliferative effects of a combination of XVX and AVNs, in an *in vitro* model  
267 of colon and liver cancer cell lines. Our results showed that XVX and AVNs, used individually, were able to inhibit the  
268 proliferation of both CaCo-2 and HepG2 cancer cells, without inducing cytotoxic effects on normal human NCTC 2544  
269 cells. Regarding the two AVN fractions that we isolated, P4 (AVNs mix) was more active as an antiproliferative agent,  
270 than P3 (AVN B). This may be explained by a synergy among the AVN A, B, C forms contained in P4, an hypothesis  
271 which is sustained by the higher ORAC and CAA of P4, compared to P3.

272 Our results also demonstrated that the combination XVX+AVNs mix (P4) showed a greater inhibition of proliferation  
273 rate than XVX and AVNs used alone. This antiproliferative effect was exerted through the ability of the XVX+AVNs to  
274 activate both intrinsic and extrinsic apoptotic pathways. In fact, caspase 3 activity was increased to a greater extent by  
275 XVX+AVNs than by the individual compounds, in both cancer cell lines. It has already been shown that XVX exerts its

276 anticancer effect through the activation of the effector caspase 3 in several cancer cell lines [5, 34], but this is the first  
277 time that such a remarkable increase in caspase 3 activity was identified in the presence of the couple XVX+AVNs in  
278 CaCo-2 and HepG2 cancer cell lines.

279 Another interesting aspect of this report was the effect exerted by our phytochemicals on the modulation of some genes,  
280 which are fundamental for cancer cell survival.

281 In fact, our data showed that the XVX+AVNs combination remarkably reduced the expression levels of the pro-survival  
282 factors: BIRC5, HIF1A and VEGFA. The rationale for the choice of these genes among the many others possible  
283 markers, in this research, derived from previous works, showing that XVX downregulated BIRC5 in T24 bladder cancer  
284 cells [34], and vitexin, the mono glucoside of apigenin, was able to decrease the activity of HIF1 $\alpha$  and downregulate the  
285 expression levels of its target gene VEGFA [39]. Our results confirm the previous results and underline the remarkable  
286 capacity of the XVX+AVNs combination to reduce the anti-apoptotic defenses of the CaCo-2 and HepG2 cancer cell  
287 lines, influencing the expression of the members of the IAPs family, in which survivin, the BIRC5 gene product, is  
288 enclosed [40].

289 Notably, XVX treatment was the most cytotoxic on CaCo-2 cells, while the AVNs treatment was the most cytotoxic on  
290 HepG2 cells, but when utilized in the mixture, the antiproliferative effect of XVX+AVNs combination was greater in  
291 HepG2 than in CaCo-2 cells. We hypothesized that this different behavior could be linked to the different genetic  
292 background of the two cancer cell lines, as CaCo-2 cells possess a mutated TP53 gene, whereas HepG2 cells a wild type  
293 TP53 gene. We believe that in HepG2 cells, the p53 protein levels could be increased by the phytochemical  
294 combination, leading to activation of apoptosis, as it was demonstrated by others for all-trans retinoic acid [29].  
295 However, the clarification of this aspect deserves further research.

296 In conclusion, our work shows that the combined action of XVX and AVNs (P4) induces both intrinsic and extrinsic  
297 apoptotic pathways on CaCo-2 and HepG2 cancer cells, as well as by the downregulation of the pro-survival factors  
298 BIRC5, HIF1A and VEGFA in both cancer cell lines.

299 XVX and AVNs derive from renewable vegetable sources and their purification can be scaled up for a wider request of  
300 these phytochemicals for nutraceutical preparations, as the synthesis of these molecules is difficult, expensive and, for  
301 XVX, not fully feasible. Our *in vitro* study creates the basis for the possible use of this combined treatment for  
302 chemoprevention against the insurgence of both colon and liver cancers also *in vivo*.

303

304 **Conflict of Interest** On behalf of all authors, the corresponding author states that there is no conflict of interest.

305

306 **Abbreviations**

307 AVNs, avenanthramides  
308 BIRC5, Baculoviral Inhibitor of apoptosis Repeat-Containing 5  
309 BVc, *Beta vulgaris* var. *cicla* L.  
310 CAA, Cellular Antioxidant Activity  
311 DCFH-DA, 2',7'-dichlorodihydrofluorescein diacetate  
312 HIF1A, Hypoxia Inducible Factor 1A  
313 HPLC, High Pressure Liquid Chromatography  
314 IAPs, Inhibitor of Apoptosis Proteins  
315 MS, Mass Spectrometry  
316 ORAC, Oxygen Radical Absorbance Capacity  
317 PDA Photo Diode Array  
318 SRB, Sulforhodamine B  
319 UV, Ultraviolet  
320 VEGF, Vascular Endothelial Growth Factor  
321 XVX, vitexin-2-O-xyloside

322

## 323 **References**

- 324 1. Ninfali P, Bacchiocca M, Antonelli A, Biagiotti E, Di Gioacchino AM, Piccoli G, Stocchi V, Brandi G  
325 (2007) Characterization and biological activity of the main flavonoids from Swiss Chard (*Beta vulgaris*  
326 subspecies *cicla*). *Phytomedicine* 14:216-221
- 327 2. Ninfali P, Angelino D (2013) Nutritional and functional potential of *Beta vulgaris cicla* and *rubra*.  
328 *Fitoterapia* 89:188-199
- 329 3. Gennari L, Felletti M, Blasa M, Angelino D, Celeghini C, Corallini A, Ninfali P (2011) Total Extract of  
330 *Beta Vulgaris* Var. *Cicla* Seeds versus Its Purified Phenolic Components: Antioxidant Activities and  
331 Antiproliferative Effects Against Colon Cancer Cells. *Phytochem Analysis* 22:272-279
- 332 4. Papi A, Farabegoli F, Iori R, Orlandi M, De Nicola GR, Bagatta M, Angelino D, Gennari L, Ninfali P  
333 (2013) Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth  
334 and apoptosis of colon cancer cells. *Food Chem* 138:1521-1530

- 335 5. Farabegoli F, Scarpa ES, Frati A, Serafini G, Papi A, Spisni E, Antonini E, Benedetti S, Ninfali P (2017)  
336 Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells. *Food Chem* 218:356-364
- 337 6. Peterson DM (2001) Oat antioxidants. *J Cereal Sci* 33:115-129
- 338 7. Collins FW (1989) Oat phenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids  
339 from oat groats and hulls. *J Agr Food Chem* 37:60-66
- 340 8. Antonini E, Lombardi F, Alfieri M, Diamantini G, Redaelli R, Ninfali P (2016) Nutritional characterization  
341 of naked and dehulled oat cultivar samples at harvest and after storage. *J Cereal Sci* 72:46-53
- 342 9. Skoglund M, Peterson DM, Andersson R, Nilsson J, Dimberg LH (2008) Avenanthramide content and  
343 related enzyme activities in oats as affected by steeping and germination. *J Cereal Sci* 48:294-303
- 344 10. Xu JG, Tian CR, Hu QP, Luo JY, Wang XD, Tian XD (2009) Dynamic changes in phenolic compounds  
345 and antioxidant activity in oats (*Avena nuda* L.) during steeping and germination. *J Agr Food Chem*  
346 57:10392-10398
- 347 11. Chen CY, Milbury PE, Kwak HK, Collins FW, Samuel P, Blumberg JB (2004) Avenanthramides and  
348 phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and  
349 human LDL resistance to oxidation. *J Nutr* 134:1459-1466
- 350 12. Chen CYO, Milbury PE, Collins FW, Blumberg JB (2007) Avenanthramides are bioavailable and have  
351 antioxidant activity in humans after acute consumption of an enriched mixture from oats. *J Nutr* 137:1375-  
352 1382
- 353 13. Koenig RT, Dickman JR, Wise ML, Ji LL (2011) Avenanthramides Are Bioavailable and Accumulate in  
354 Hepatic, Cardiac, and Skeletal Muscle Tissue Following Oral Gavage in Rats. *J Agr Food Chem* 59:6438-  
355 6443
- 356 14. Meydani M (2009) Potential health benefits of avenanthramides of oats. *Nutr Rev* 67:731-735
- 357 15. Guo WM, Nie L, Wu DY, Wise ML, Collins FW, Meydani SN, Meydani M (2010) Avenanthramides  
358 Inhibit Proliferation of Human Colon Cancer Cell Lines In Vitro. *Nutr Cancer* 62:1007-1016
- 359 16. Holdenrieder S, Stieber P (2004) Apoptotic markers in cancer. *Clin Biochem* 37:605-617

- 360 17. Samali A, Jager R (2014) Mechanisms of resistance to cell death pathways in cancer cells. In: McManus  
361 LM, Mitchell RN (eds) Pathobiology of Human Disease, 1st edn. Elsevier Inc., Atlanta, pp 393-402
- 362 18. Altieri DC (2013) Targeting survivin in cancer. *Cancer Lett* 332:225-228
- 363 19. Johnson ME, Howerth EW (2004) Survivin: A bifunctional inhibitor of apoptosis protein. *Vet Pathol*  
364 41:599-607
- 365 20. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646-674
- 366 21. Gomez-Roman N, Sahasrabudhe NM, McGregor F, Chalmers AJ, Cassidy J, Plumb J (2016) Hypoxia-  
367 inducible factor 1 alpha is required for the tumorigenic and aggressive phenotype associated with Rab25  
368 expression in ovarian cancer. *Oncotarget* 7:22650-22664
- 369 22. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. *J Mol Med-Jmm* 85:1301-1307
- 370 23. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-Inducible Factor-1 Is A Basic-Helix-Loop-  
371 Helix-Pas Heterodimer Regulated by Cellular O-2 Tension. *P Natl Acad Sci USA* 92:5510-5514
- 372 24. Baba Y, Noshio K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS,  
373 Ogino S (2010) HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal  
374 cancers. *Am J Pathol* 176:2292-2301
- 375 25. Ferrara N (2005) VEGF as a therapeutic target in cancer. *Oncology* 69:11-16
- 376 26. Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon  
377 cancer: biology and therapeutic implications. *Oncologist* 5:11-15
- 378 27. Doll JA, Hobbs JE, Soff JA (2007) Role of apoptosis in anti-angiogenic cancer therapies. In: Gewirtz DA,  
379 Holt SE, Grant S (eds) Apoptosis and Senescence in Cancer Chemotherapy and Radiotherapy, 2nd edn.  
380 Humana Press, Totowa, pp 537-555
- 381 28. Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR (2009) Redox Mechanisms Involved in the  
382 Selective Activation of Nrf2-mediated Resistance Versus p53-dependent Apoptosis in Adenocarcinoma  
383 Cells. *J Biol Chem* 284:27721-27733

- 384 29. Heo SH, Kwak J, Jang KL (2015) All-trans retinoic acid induces p53-dependent apoptosis in human  
385 hepatocytes by activating p14 expression via promoter hypomethylation. *Cancer Lett* 362:139-148
- 386 30. Ye RP, Chen ZD (2016) Saikosaponin A, an active glycoside from *Radix bupleuri*, reverses P-glycoprotein-  
387 mediated multidrug resistance in MCF-7/ADR cells and HepG2/ADM cells. *Xenobiotica* 1-9
- 388 31. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence  
389 and mortality in Europe in 2006. *Ann Oncol* 18:581-592
- 390 32. Liu LP, Zubik L, Collins FW, Marko M, Meydani M (2004) The antiatherogenic potential of oat phenolic  
391 compounds. *Atherosclerosis* 175:39-49
- 392 33. Ninfali P, Gennari L, Biagiotti E, Cangi F, Mattoli L, Maidecchi A (2009) Improvement in botanical  
393 standardization of commercial freeze-dried herbal extracts by using the combination of antioxidant capacity  
394 and constituent marker concentrations. *J AOAC Int* 92:797-805
- 395 34. Scarpa ES, Emanuelli M, Frati A, Pozzi V, Antonini E, Diamantini G, Di RG, Sartini D, Armeni T, Palma  
396 F, Ninfali P (2016) Betacyanins enhance vitexin-2-O-xyloside mediated inhibition of proliferation of T24  
397 bladder cancer cells. *Food Funct*. doi:10.1039/c6fo01130f
- 398 35. Peterson DM, Hahn MJ, Emmons CL (2002) Oat avenanthramides exhibit antioxidant activities in vitro.  
399 *Food Chem* 79:473-478
- 400 36. Blasa M, Angelino D, Gennari L, Ninfali P (2011) The cellular antioxidant activity in red blood cells  
401 (CAA-RBC): A new approach to bioavailability and synergy of phytochemicals and botanical extracts.  
402 *Food Chem* 125:685-691
- 403 37. Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, Chen YC (2015) Dietary compounds galangin and  
404 myricetin suppress ovarian cancer cell angiogenesis. *J Funct Foods* 15:464-475
- 405 38. Angelino D, Berhow M, Ninfali P, Jeffery EH (2013) Caecal absorption of vitexin-2-O-xyloside and its  
406 aglycone apigenin, in the rat. *Food Funct* 4:1339-1345
- 407 39. Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y (2006) Vitexin, an HIF-1 $\alpha$  inhibitor, has anti-  
408 metastatic potential in PC12 cells. *Mol Cells* 22:291-299

409 40. Ma J, Feng Y, Liu Y, Li X (2016) PUMA and survivin are involved in the apoptosis of HepG2 cells  
410 induced by microcystin-LR via mitochondria-mediated pathway. *Chemosphere* 157:241-249

411

412 **Figure captions**

413 **Fig. 1** Elution profile showing the four main peaks (P1-P4) obtained from the Sephadex LH-20 column  
414 chromatography loaded with the extract of milled oat (a); HPLC profile of P3 (b) and P4 (c), used for the  
415 cytotoxicity assays. P3 contains the AVN B (B); P4 contains a mixture of peaks, corresponding to AVN C (C),  
416 AVN A (A), AVN B (B) and other minor AVNs (peaks 1-4). The structural formulae are also shown

417 **Fig. 2** The antiproliferative effects of P3, P4 and XVX on CaCo-2 colon cancer cells (a, c, e) and HepG2 liver  
418 cancer cells (b, d, f), after 48h treatment. Data were expressed as percentage of cell viability relative to the control,  
419 represented by the corresponding untreated cells. Three replicate experiments with three samples analyzed for each  
420 replicate (n=9) were performed \*p<0.05, \*\*p<0.01, \*\*\*p<0.001


421 **Fig. 3** Evaluation of caspase 3, caspase 9 and caspase 8 activity levels, induced by XVX, P3 and P4 in CaCo-2 (a,  
422 c, e, respectively) and HepG2 (b, d, f, respectively) cancer cells. Cells were untreated (CTRL), or treated for 48h  
423 with P3 (120  $\mu$ M), or P4 (120  $\mu$ M) or XVX (50  $\mu$ M). Data were expressed as % caspase 3 (a, b), % caspase 9 (c,  
424 d), % caspase 8 (e, f) activity levels. Three replicate experiments with two samples analyzed for each replicate  
425 (n=6) were performed. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001


426 **Fig. 4** Representative images of DCFH-DA assay in CaCo-2 (a) and in HepG2 (b) cells treated with  
427 phytochemicals before H<sub>2</sub>O<sub>2</sub> treatment. CTRL, untreated cells; H<sub>2</sub>O<sub>2</sub>, cells treated with 1 mM H<sub>2</sub>O<sub>2</sub> for 1 h; P4 (60  
428  $\mu$ M), cells treated with 60  $\mu$ M P4 for 24h and then with 1 mM H<sub>2</sub>O<sub>2</sub> for 1 h; P3 (60  $\mu$ M), cells treated with 60  $\mu$ M  
429 P3 for 24h and then with 1 mM H<sub>2</sub>O<sub>2</sub> for 1 h; P4 (30  $\mu$ M), cells treated with 30  $\mu$ M P4 for 24h and then with 1  
430 mM H<sub>2</sub>O<sub>2</sub> for 1 h; P3 (120  $\mu$ M), cells treated with 120  $\mu$ M P3 for 24h and then with 1 mM H<sub>2</sub>O<sub>2</sub> for 1 h (c, d).  
431 Three fields per sample were analyzed and each time at least 100 cells were counted; three independent  
432 experiments were performed for both CaCo-2 and HepG2 cancer cells (n=9) and results were expressed as % DCF  
433 fluorescent positive cells versus control; \*\*p<0.01, \*\*\*p<0.001


434 **Fig. 5** The antiproliferative effect of XVX+P4 combination on CaCo-2 colon cancer cells (a) and HepG2 liver  
435 cancer cells (b), after 48h treatment. Data were expressed as percentage of cell viability relative to the control,  
436 represented by the corresponding untreated cells. Three replicate experiments with three samples analyzed for each  
437 replicate (n=9) were performed \*\*p<0.01, \*\*\*p<0.001


438 **Fig. 6** Evaluation, through RTqPCR assay, of the effects of XVX, P4 and their combination on BIRC5, HIF1A  
439 and VEGFA expression levels in CaCo-2 (a, c, e) and HepG2 (b, d, f) cancer cells. BIRC5 (a, b), HIF1A (c,


440 d), VEGFA (e, f) mRNA levels were measured and normalized to the mRNA levels of the housekeeping  
441 gene  $\beta$ -actin. Results obtained from untreated cells (CTRL) and from CaCo-2 and HepG2 cells treated with  
442 XVX (50  $\mu$ M), P4 (120  $\mu$ M), or XVX+P4 (50  $\mu$ M XVX+120  $\mu$ M P4) for 24h, are shown. Three replicate  
443 experiments with three samples analyzed for each replicate (n=9) were performed. \*p<0.05, \*\*p<0.01,  
444 \*\*\*p<0.001














**Table 1.** HPLC-PDA-MS characterization of AVNs purified from P3 and P4 fractions and antioxidant capacity (ORAC) of the dried fractions.

	AVN type	t <sub>R</sub> <sup>a</sup>	% <sup>b</sup>	m/z <sup>a</sup>	UV <sup>a</sup> (λ <sub>max</sub> )	ORAC (μmolTE/g)
<b>P3</b>	B	34.2	95 ± 2	329	342	6,547 ± 290
	C	29.4	37 ± 2	315	343	
<b>P4</b>	A	33.1	35 ± 1	299	319	19,079 ± 474
	B	34.2	8 ± 1	329	342	

<sup>a</sup> t<sub>R</sub>, m/z, UV spectra were compared with those of the external AVN A, B, C standards, and the peak areas were used for quantification.  
<sup>b</sup> AVN average percentages found in the P3 and P4 fractions, obtained from three different purification batches.

**Table 2.** Caspases 3, 9 and 8 activity levels, after 48h treatment with XVX+P4 combination, on CaCo-2 and HepG2 cells.

	CaCo-2		HepG2	
	CTRL	XVX + P4	CTRL	XVX+P4
<b>Caspase 3</b>	100 ± 5	229 ± 17**	100 ± 4	352 ± 47***
<b>Caspase 9</b>	100 ± 3	205 ± 14**	100 ± 5	229 ± 26**
<b>Caspase 8</b>	100 ± 4	309 ± 16***	100 ± 3	191 ± 21*

Three replicate experiments with two samples analyzed for each replicate (n=6) were performed.

\* p<0.05, \*\* p<0.01, \*\*\* p<0.001. Cells were treated with 50 µM XVX+120 µM P4.



Click here to access/download

**Electronic Supplementary Material**  
ESM\_1.pdf

